After chemotherapy, patients with AML may continue to show evidence of pre-malignant clones or clonal hematopoiesis of indeterminate potential (CHIP) that does not readily portend relapse [12].These genes (DNMT3A, TET2, ASXL1, etc.)are of questionable utility as MRD markers in the post-chemotherapy setting [29–32]. Here, ASXL1 is linked to acute myeloid leukemia.